- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02326428
SITS (Safe Implementation of Treatments in Stroke) Open Artery by Thrombectomy in Acute Occlusive Stroke Study (SITS Open)
March 14, 2018 updated by: Nils Wahlgren, MD, PhD, FESO, Karolinska Institutet
An Open, Prospective, Blinded Evaluation, International, Multicentre, Controlled Study of Safety and Efficacy of Thrombectomy and Standard Stroke Care in Clinical Routine Treatment of Acute Occlusive Stroke Compared to Standard Stroke Care Only
Ischemic stroke, i.e. irreversible damage of a part of the patient's brain, is caused by the formation of blood clot in the major vessel which gives blood supply to a certain part of the brain.
At early time, within the first 4,5 hours, the conventional treatment is to try to dissolve this blood clot with a medication ("thrombolytic drug") which is administered to the blood through the needle in the vein.
If the clot still remains there, additional treatment is possible - going directly to the clot via artery and taking it out with a special device.
Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
The purpose of the present study is to evaluate the benefit and safety efficacy of thrombectomy and standard stroke care in clinical routine treatment of acute occlusive stroke compared to standard stroke care only.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
341
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Karolinska University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Patients with acute stroke after exclusion of intracranial haemorrhage on CT/MRI scan.
- Confirmed diagnosis on CTA of persisting occlusion of the terminal Internal Carotid Artery (Car-T), proximal Middle Cerebral Artery (MCA, M1), proximal part of the insular segment of MCA (M2), proximal part of the anterior cerebral artery (A1), Basilar Artery (BA) or proximal part of the posterior cerebral artery (P1), consistent with the clinical symptoms. For inclusion in the study, CTA must not be performed later than 15 minutes after IVT start if given. For patients not treated with IVT, CTA should preferably be performed within 15 minutes of completion of the non-contrast CT but must be performed within 6 hours after stroke onset.
- Eligible patients for IVT are treated according to clinical guidelines (Attachment 1), and IVT, if given, initiated within 4.5 h.
- Initiation of thrombectomy is recommended within 6 hours after stroke onset but must be performed within to 8 hours if thrombectomy would still be of benefit for the patient as judged by the investigator.
- Baseline NIHSS Score at initiation of IVT is recommended between 7 and 25 for anterior circulation stroke and ≥7 without upper limit for posterior circulation stroke (baseline NIHSS score should be assessed by an NIHSS-certified physician), but patients may also be included beyond these scores if thrombectomy would still be of benefit for the patient as judged by the investigator.
- Age ≥18years.
- Anticipated life expectancy of at least 6 months.
- Patient or legal representative is competent to make a decision and has provided informed consent with regard to participation in the study, retrieval and storage of data and follow up procedures.
- Initiation of endovascular procedure (DSA/TBY, defined as start with groin puncture) within 2 hours from the start of IVT, or after CTA if IVT is not given (for TBY arm patients).
Exclusion criteria:
- Known significant pre-stroke disability (mRS ≥2).
- Extended early ischemic changes for basilar artery occlusion, according to the judgment of treating physician based on routine clinical practice of the hospital; if technical possibility exists, early irreversible ischemic changes may be confirmed by pc-ASPECTS score < 8 on CTASI (2) or extensive DWI lesion on pre-treatment MRI.
- Known pregnancy.
- Participation in any other investigational drug or device study, currently or in the previous 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Thrombectomy
Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator.
Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
|
Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
Other Names:
Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
Other Names:
|
Active Comparator: Control
Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy.
Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator.
Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
|
Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Categorical shift in modified Rankin Scale score at 3 months
Time Frame: 90 (range 76-104) days from stroke onset
|
Categorical shift towards better stroke outcome as reflected by lower, i.e. better, Rankin Scale scores over the range of the scale in active compared to control group.
|
90 (range 76-104) days from stroke onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional independence at 3 months after stroke onset
Time Frame: 90 (76-104) days after stroke onset
|
Proportion of patients with functional independence (modified Rankin Scale, mRS, score 0-2) at 3 months after stroke onset
|
90 (76-104) days after stroke onset
|
Excellent recovery at 3 months
Time Frame: 90 (76-104) days after stroke onset
|
Proportion of patients with excellent outcome (mRS score 0-1) at 3 months
|
90 (76-104) days after stroke onset
|
Length of in-hospital stay
Time Frame: 90 (76-104) days after stroke onset
|
Days to discharge from in-hospital ward to home/secondary care for survivors in thrombectomy vs. control
|
90 (76-104) days after stroke onset
|
Home time stay
Time Frame: 90 (76-104) days after stroke onset
|
Number of days the patient stayed at home or at relative's stay within the first 3 months after stroke onset, in thrombectomy vs. control
|
90 (76-104) days after stroke onset
|
Recurrent stroke within 3 months
Time Frame: 90 (76-104) days after stroke onset
|
90 (76-104) days after stroke onset
|
|
Recanalisation of the occluded artery for thrombectomy treated population
Time Frame: 6h
|
Recanalisation of the occluded artery for thrombectomy treated population, defined as at least TICI 2b flow in the treated territory after procedure
|
6h
|
Time to revascularisation
Time Frame: 6h
|
Time from stroke onset to revascularisation to any TICI (Thrombolysis in Cerebral Infarction) grade (2b-3 by core lab evaluation) for the actively treated population
|
6h
|
Recanalisation of the occluded artery at 24h computerized tomography angiography /contrast-enhanced magnetic resonance angiography
Time Frame: 22-36h
|
Defined as AOL 2-3
|
22-36h
|
Proportion of patients with recanalisation before thrombectomy
Time Frame: 6h
|
Defined as AOL 2-3
|
6h
|
Reduction of infarct size
Time Frame: 22-36h
|
Reduction in infarct size (thrombectomy vs. control) at 22-36 hours
|
22-36h
|
Neurological and functional improvement in relation to thrombus length
Time Frame: 90 (76-104) days
|
Neurological improvement (difference in National Institute of Health Stroke Scale from baseline to 12h, to 24h and to 7D after initiation of intravenous thrombolysis, or discharge if earlier), and functional outcome at 3 months in relation to recanalisation status and thrombus length (mm)
|
90 (76-104) days
|
All-cause mortality at 3 months
Time Frame: 90 (76-104) days
|
90 (76-104) days
|
|
Neurological death within 7 days post treatment
Time Frame: 7 days
|
7 days
|
|
Distal embolism/reocclusion demonstrated by follow-up computerized tomography angiography /contrast-enhanced magnetic resonance angiography
Time Frame: 22-36h
|
Distal embolism/reocclusion will be evaluated by DSA immediately following the endovascular intervention and at the 22-36 hour follow up CT and CTA scans.
The proportion of patients with recanalisation of the target occlusion and distal enbolism/reocclusion will be calculated.
|
22-36h
|
Embolism into new territories (ENT)
Time Frame: 22-36h
|
22-36h
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptomatic intracerebral haemorrhage (SICH) according to SITS-MOST definition
Time Frame: 22-36 h
|
• Symptomatic intracerebral haemorrhage (SICH) according to SITS-MOST definition: local or remote parenchymal haemorrhage type 2 on the 22- to 36-hour post-treatment imaging scan, combined with a neurological deterioration of ≥4 points compared with baseline NIHSS or the lowest NIHSS value or death between baseline and 24 hours.
|
22-36 h
|
Symptomatic intracerebral haemorrhage (SICH) according to modified SITS-MOST definition
Time Frame: 22-36h
|
• Symptomatic intracranial haemorrhage (SICH) according to modified SITS-MOST definition; in addition to usual SITS-MOST criteria blood may be anywhere in the intracranial space (including in the intraventricular, intraparenchymal and/or subarachnoid space).
|
22-36h
|
Symptomatic intracerebral haemorrhage (SICH) according to modified ECASS III definition
Time Frame: 22-36h
|
• Symptomatic intracranial haemorrhage (SICH) defined as an NIHSS decline of ≥4 points compared with baseline NIHSS or the lowest NIHSS value or death between baseline and 7 days, associated with any haemorrhage judged by core lab evaluation to be responsible for the decline.
Blood may be anywhere in the intracranial space including in the intraventricular, intraparenchymal and/or subarachnoid space (modified ECASS III definition).
|
22-36h
|
Number of adverse effects of thrombectomy
Time Frame: up to 90 (76-104) days
|
Any adverse reactions related to thrombectomy procedure including patients for whom the initiating angiography revealed recanalisation by IVT only
|
up to 90 (76-104) days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Nils Wahlgren, Professor, Karolinska Institutet
- Study Chair: Olav Jansen, Professor, University Hospital of Schleswig-Holstein
- Principal Investigator: Staffan Holmin, M.D., Ph.D., Karolinska University Hospital, Karolinska Institutet
- Principal Investigator: Kennedy Lees, M.D., FRCP, University of Glasgow
- Principal Investigator: Salvatore Mangiafico, M.D., Ph., Careggi University Hospital
- Principal Investigator: Lawrence Wong, M.D., Ph.D., Chinese University of Hong Kong
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
January 1, 2018
Study Completion (Actual)
January 1, 2018
Study Registration Dates
First Submitted
May 21, 2014
First Submitted That Met QC Criteria
December 22, 2014
First Posted (Estimate)
December 29, 2014
Study Record Updates
Last Update Posted (Actual)
March 15, 2018
Last Update Submitted That Met QC Criteria
March 14, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SITS Open
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Stent retriever endovascular device for thrombectomy
-
Oxford University Hospitals NHS TrustMedtronic; Terumo CorporationRecruitingMyocardial Infarction | Coronary Artery Disease | ThrombusUnited Kingdom
-
Gregory W AlbersMedical University of South Carolina; National Institute of Neurological Disorders... and other collaboratorsTerminatedCerebral Infarction | Stroke, AcuteUnited States
-
Hopital FochRecruiting
-
Hopital FochRecruitingStroke, AcuteFrance
-
Beijing Tiantan HospitalRecruitingBasilar Artery Occlusion | Endovascular TreatmentChina
-
Medical University of South CarolinaUniversity of California, Los Angeles; National Institute of Neurological Disorders... and other collaboratorsNot yet recruitingIschemic Stroke
-
Federico II UniversityCompletedST-elevation Myocardial Infarction | Thrombus | StentsItaly
-
Matthew EagletonMassachusetts General HospitalEnrolling by invitationAortic Dissection | Ascending Aortic Dissection | Thoracoabdominal Aortic Aneurysm | Thoracic Aortic Aneurysms | Dissecting, Aneurysm | Ascending Aorta Aneurysm | Aortic Arch; Aneurysm, Dissecting | Renal Artery Aneurysm | Superior Mesenteric Artery AneurysmUnited States
-
Raul NogueiraStryker Neurovascular; Berry Consultants; Brainstorme Imaging Core Lab IncRecruitingIschemic StrokeUnited States
-
IRCCS San RaffaeleCompletedAneurysm Thoracic | Aneurysm Abdominal | Renal AneurysmUnited States, France, Italy, United Kingdom, Germany, Spain, Denmark, Sweden